Financial Statements Company Balance Sheet at 31December AstraZeneca PLC 2016 2015 Notes $m $m Fixed assets Fixed asset investments 1 30,449 30,047 Current assets Debtors other 14 15 Debtors amounts owed by Group undertakings 8,935 7,283 8,949 7,298 Creditors: Amounts falling due within one year Non-trade creditors 2 518 814 Interest-bearing loans and borrowings 3 1,749 2,267 814 Net current assets 6,682 6,484 Total assets less current liabilities 37,131 36,531 Creditors: Amounts falling due after more than one year Amounts owed to Group undertakings 3 283 283 Interest-bearing loans and borrowings 3 14,138 13,705 14,421 13,988 Net assets 22,710 22,543 Capital and reserves Called-up share capital 4 316 316 Share premium account 4,351 4,304 Capital redemption reserve 153 153 Other reserves 2,583 2,623 Profit and loss account 15,307 15,147 Shareholders funds 22,710 22,543 $m means millions of US dollars.
The Company Financial Statements from page198 to 202 were approved by the Board on 2 February 2017 and were signed on its behalfby Pascal Soriot Marc Dunoyer Director Director Companys registered number 02723534 198 AstraZeneca Annual Report and Form 20-F Information 2016 Financial Statements Statement of Changes in Equity for the year ended 31December Share Capital Share premium redemption Other Profit and Total capital account reserve reserves loss account equity $m $m $m $m $m $m At 1 January 2015 316 4,261 153 2,754 16,709 24,193 Total comprehensive income for the period Profit for the period 1,974 1,974 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 1,975 1,975 Transactions with owners, recorded directly in equity Dividends 3,537 3,537 Equity-settled share-based payment transactions 131 131 Issue of Ordinary Shares 43 43 Total contributions by and distributions to owners 43 131 3,537 3,625 At 31December 2015 316 4,304 153 2,623 15,147 22,543 Total comprehensive income for the period Profit for the period 3,699 3,699 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 3,700 3,700 Transactions with owners, recorded directly in equity Dividends 3,540 3,540 Equity-settled share-based payment transactions 40 40 Issue of Ordinary Shares 47 47 Total contributions by and distributions to owners 47 40 3,540 3,533 At 31December 2016 316 4,351 153 2,583 15,307 22,710 At 31December 2016, $15,307m 2015:$15,147m of the profit and loss account reserve was available for distribution.
Included in other reserves is a special reserve of $157m 2015:$157m, arising on the redenomination of share capital in 1999.
Included within other reserves at 31December 2016 is $742m 2015:$782m in respect of cumulative share-based payment awards.
These amounts are not available for distribution.
AstraZeneca Annual Report and Form 20-F Information 2016 199
